The American Medical Association (AMA), which is holding its annual meeting this week in Chicago, Illinois, has issued a call for intensified oversight of the pharmacy benefit manager (PBM) industry.
The American Medical Association (AMA), which is holding its annual meeting this week in Chicago, Illinois, has issued a call for intensified oversight of the pharmacy benefit manager (PBM) industry.
“It’s time to pull back the curtain on pharmacy benefit managers and how their practices negatively impact patients,” said Russell Kridel, MD, a member of the AMA board of trustees, in a statement announcing adoption of the policy. “How is it that PBMs and health plans profit from negotiated discounts on prescription drugs while patients pay co-pays based on high drug list prices that even the plans themselves are not paying? Because of market concentration and lack of transparency, patients and physicians are essentially powerless in the face of PBM pricing and coverage decisions,” he added.
According to the AMA, PBMs have similar roles to insurers, yet face no similar oversight, and are hampering policymakers’ efforts to reduce drug costs with their “byzantine” confidential contracts that drive increased costs for drugs without justification.
The new policy calls for active regulation of PBMs by state departments of insurance, application of rebates to drug prices at the point of sale, efforts to ensure that no patients are discriminated against in benefit design, and increased transparency in how direct and indirect remuneration fees are calculated.
AMA also calls for increased PBM transparency, including disclosure of information on topics like rebates, discounts, and utilization; pharmacy and therapeutics committee information; and formulary information, which AMA says should be made available to patients and prescribers at the point of care.
AMA says that it will develop model legislation addressing state-level regulation of PBMs for policymakers to use.
In addition to its attempt to promote policy solutions, the AMA also seeks to get patients involved; the organization’s new policy is linked with AMA’s TruthinRx campaign, a resource for patients to learn about what influences the price of drugs, how drug prices for products like insulin are increasing over time despite competition, and the role of PBMs in negotiating discounts and rebates with drug makers.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.